An IL-23 related disease, in particular an inflammatory disease such as psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA) (ankylosing spondylitis and ax-SpA without X-ray findings). Method of treating). A method comprising the step of administering an anti-IL-23A antibody to a patient, comprising the steps of: a) administering an initial dose of the anti-IL-23A antibody to the patient； and b) administering the initial dose. Administering a first maintenance dose of said anti-IL-23A antibody to the patient after 4 to 24 weeks, such as 4 to 12 weeks, such as 6 to 24 weeks, such as 6 to 12 weeks； and c ) At least one additional maintenance dose is given to the patient 4 to 24 weeks, eg 4 to 12 weeks, eg 6 to 24 weeks, eg 6 to 12 weeks after the first maintenance dose is administered. The method, comprising the step of administering. [Selection diagram] None【課題】ＩＬ－２３関連疾患、特に炎症性疾患、例えば乾癬、乾癬性関節炎又は体軸性（脊髄）脊椎関節炎（ａｘ－ＳｐＡ）（強直性脊椎炎及びＸ線所見が認められないａｘ－ＳｐＡを含む）を処置するための方法の提供。【解決手段】抗ＩＬ－２３Ａ抗体を患者に投与する工程を含む方法であって、ａ）初回用量の前記の抗ＩＬ－２３Ａ抗体を患者に投与する工程；ｂ）前記の初回用量が投与された４～２４週間後、例えば４～１２週間後、例えば６～２４週間後、例えば６～１２週間後に、１回目の維持用量の前記の抗ＩＬ－２３Ａ抗体を患者に投与する工程；及びｃ）前記の１回目の維持用量が投与された４～２４週間後、例えば４～１２週間後、例えば６～２４週間後、例えば６～１２週間後に、少なくとも１回の追加の維持用量を患者に投与する工程を含む、該方法。【選択図】なし
